Efficacy and Safety of Microencapsulated Benzoyl Peroxide 3% and Microencapsulated Tretinoin 0.1% (E-Bpo/E-Atra) in Acne Vulgaris: Results from Two Randomized Controlled Clinical Trials

Main Article Content

J Del Rosso
JDR Research, Las Vegas, NV

O Levy-Hacham
University of California -San Francisco, San Francisco, CA

O Mizrahi
Sol-Gel Technologies Ltd,Ness Ziona, Israel

Keywords

Acne Vulgaris, Benzoyl Peroxide, Topical Retinoid, Safety, Efficacy

Abstract

Abstract not available.

References

1. Zaenglein AL, et al. J Am Acad Dermatol. 2016;74:945-973 e933

2. Walsh TR, et al. Lancet Infect Dis.2016;16:e23-33;

3. Matin T, Goodman MB. 2019. Available from http://www.ncbi.nlm.nih.gov/books/ NBK537220/

4. Kawashima M, et al. JDermatol. 2017;44:1212-1218

5. Kircik LH. J Drugs Dermatol. 2013;12:s73-76

6. Sagransky M, et al. Expert Opin Pharmacother.2009;10:2555-2562;

7. Fakhouri T, et al. J Drugs Dermatol. 2009;8:657-661

8. Martin B, et al. Br J Dermatol. 1998;139 (Suppl 52):8-11

9. Patel VB, et al. Drug Dev Ind Pharm. 2001;27:863-869

10. Quigley JW, Bucks DA. J Am Acad Dermatol. 1998;38:S5-10

11. Brand B, et al. J Am Acad Dermatol. 2003;49 (3Suppl):S227-232.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.24

Article Details

How to Cite
Del Rosso, J., Levy-Hacham, O., & Mizrahi, O. (2021). Efficacy and Safety of Microencapsulated Benzoyl Peroxide 3% and Microencapsulated Tretinoin 0.1% (E-Bpo/E-Atra) in Acne Vulgaris: Results from Two Randomized Controlled Clinical Trials. SKIN The Journal of Cutaneous Medicine, 5(1), s24. https://doi.org/10.25251/skin.5.supp.24
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.